• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone.使用他非诺喹治疗一名患有复发性巴贝斯虫病的患者，该患者具有对阿奇霉素和阿托伐醌耐药的临床及分子证据。
IDCases. 2022 Feb 25;27:e01460. doi: 10.1016/j.idcr.2022.e01460. eCollection 2022.
2
Tafenoquine for Relapsing Babesiosis: A Case Series.泰法诺喹治疗复发巴贝虫病：病例系列。
Clin Infect Dis. 2024 Jul 19;79(1):130-137. doi: 10.1093/cid/ciae238.
3
Broad Antimicrobial Resistance in a Case of Relapsing Babesiosis Successfully Treated With Tafenoquine.用他非诺喹成功治疗的复发性巴贝斯虫病病例中的广泛抗菌药物耐药性
Clin Infect Dis. 2023 Feb 18;76(4):741-744. doi: 10.1093/cid/ciac473.
4
Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection.免疫功能低下的微小巴贝斯虫感染患者对阿奇霉素-阿托伐醌耐药的出现。
Clin Infect Dis. 2010 Feb 1;50(3):381-6. doi: 10.1086/649859.
5
Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.他非诺喹-阿托伐醌联合用药在人类巴贝斯虫病实验模型中实现了根治并赋予了无菌免疫。
J Infect Dis. 2024 Jan 12;229(1):161-172. doi: 10.1093/infdis/jiad315.
6
Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts.氯法齐明与阿托伐醌联合应用于免疫抑制宿主巴贝虫微小亚种根治的强效治疗方案。
J Infect Dis. 2022 Jan 18;225(2):238-242. doi: 10.1093/infdis/jiab537.
7
Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.利妥昔单抗和慢性淋巴细胞白血病相关复发性微小巴贝斯虫感染的阿托伐醌和阿奇霉素耐药的临床和分子证据。
Clin Infect Dis. 2017 Oct 1;65(7):1222-1225. doi: 10.1093/cid/cix477.
8
Atovaquone in the treatment of Babesia microti infections in hamsters.阿托伐醌治疗仓鼠微小巴贝斯虫感染
Am J Trop Med Hyg. 1996 Aug;55(2):219-22. doi: 10.4269/ajtmh.1996.55.219.
9
Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts.氯法齐明，一种治疗严重免疫功能低下宿主巴贝虫感染的有前景的药物。
J Infect Dis. 2020 Aug 17;222(6):1027-1036. doi: 10.1093/infdis/jiaa195.
10
Failure of an Approximately Six Week Course of Tafenoquine to Completely Eradicate Infection in an Immunocompromised Patient.对于一名免疫功能低下的患者，为期约六周的tafenoquine疗程未能完全根除感染。
Pathogens. 2022 Sep 15;11(9):1051. doi: 10.3390/pathogens11091051.

引用本文的文献

1
Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate.西帕加明作为抗巴贝斯虫药物候选物的疗效及作用机制
Elife. 2025 Jun 19;13:RP101128. doi: 10.7554/eLife.101128.
2
A propidium iodide-based screen of the "Bug Box" against reveals potent inhibitors.一项基于碘化丙啶的针对“昆虫盒”的筛选发现了强效抑制剂。
Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0003525. doi: 10.1128/aac.00035-25. Epub 2025 Jun 9.
3
New insights in the diagnosis and treatment of equine piroplasmosis: pitfalls, idiosyncrasies, and myths.马焦虫病诊断与治疗的新见解：陷阱、特质与误区
Front Vet Sci. 2024 Aug 14;11:1459989. doi: 10.3389/fvets.2024.1459989. eCollection 2024.
4
Pharmacokinetics and Histotoxic Profile of a Novel Azithromycin-Loaded Lipid-Based Nanoformulation.新型阿奇霉素载脂质纳米制剂的药代动力学和组织毒性特征。
AAPS PharmSciTech. 2024 Jul 9;25(6):157. doi: 10.1208/s12249-024-02861-3.
5
Recent advances, challenges and updates on the development of therapeutics for malaria.疟疾治疗药物研发的最新进展、挑战与动态
EXCLI J. 2024 May 6;23:672-713. doi: 10.17179/excli2023-6856. eCollection 2024.
6
Tafenoquine for Relapsing Babesiosis: A Case Series.泰法诺喹治疗复发巴贝虫病：病例系列。
Clin Infect Dis. 2024 Jul 19;79(1):130-137. doi: 10.1093/cid/ciae238.
7
Effectiveness of Two New Endochin-like Quinolones, ELQ-596 and ELQ-650, in Experimental Mouse Models of Human Babesiosis.两种新型内chin样喹诺酮类药物ELQ-596和ELQ-650在人类巴贝斯虫病实验小鼠模型中的有效性。
ACS Infect Dis. 2024 Apr 12;10(4):1405-1413. doi: 10.1021/acsinfecdis.4c00143. Epub 2024 Apr 2.
8
Immune Mediators Important for a Protective Secondary Response to .对……的保护性二次反应很重要的免疫介质。 （原文似乎不完整）
Pathogens. 2024 Jan 28;13(2):123. doi: 10.3390/pathogens13020123.
9
Comparative chemical genomics in species identifies the alkaline phosphatase PhoD as a determinant of antiparasitic resistance.物种间比较化学基因组学确定碱性磷酸酶 PhoD 是抗寄生虫抗性的决定因素。
Proc Natl Acad Sci U S A. 2024 Feb 27;121(9):e2312987121. doi: 10.1073/pnas.2312987121. Epub 2024 Feb 20.
10
Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.他非诺喹-阿托伐醌联合用药在人类巴贝斯虫病实验模型中实现了根治并赋予了无菌免疫。
J Infect Dis. 2024 Jan 12;229(1):161-172. doi: 10.1093/infdis/jiad315.

本文引用的文献

1
Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis.美国传染病学会（IDSA）临床实践指南：2020 年巴贝虫病诊断与管理指南。
Clin Infect Dis. 2021 Jan 27;72(2):185-189. doi: 10.1093/cid/ciab050.
2
Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo.青蒿琥酯联合用药和他非诺喹对牛巴贝斯虫的体外活性和微小巴贝斯虫的体内活性。
Parasit Vectors. 2020 Jul 20;13(1):362. doi: 10.1186/s13071-020-04235-7.
3
Serious Infectious Complications After Rituximab Therapy in Patients With Autoimmunity: Is This the Final Word?自身免疫性疾病患者接受利妥昔单抗治疗后的严重感染并发症：这是最终定论吗？
Clin Infect Dis. 2021 Mar 1;72(5):738-742. doi: 10.1093/cid/ciaa131.
4
Tafenoquine (Arakoda; Krintafel) for malaria.他非诺喹（阿拉科达；克林塔非）用于治疗疟疾。
Med Lett Drugs Ther. 2019 Jul 1;61(1575):101-104.
5
Tafenoquine: the new kid on the block.泰法诺喹：崭露头角的新贵。
Curr Opin Infect Dis. 2019 Oct;32(5):407-412. doi: 10.1097/QCO.0000000000000574.
6
Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?泰法诺喹能否彻底改变巴贝虫病的治疗方法？
J Infect Dis. 2019 Jul 2;220(3):442-447. doi: 10.1093/infdis/jiz119.
7
Approval of Tafenoquine for Malaria Chemoprophylaxis.特非那喹用于疟疾化学预防的批准。
Am J Trop Med Hyg. 2019 Jun;100(6):1301-1304. doi: 10.4269/ajtmh.19-0001.
8
Tafenoquine - A Radical Improvement?他非诺喹——是重大改进吗？
N Engl J Med. 2019 Jan 17;380(3):285-286. doi: 10.1056/NEJMe1816383.
9
Pharmaceutical Approval Update.药品批准更新。
P T. 2018 Nov;43(11):659-661.
10
Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.利妥昔单抗和慢性淋巴细胞白血病相关复发性微小巴贝斯虫感染的阿托伐醌和阿奇霉素耐药的临床和分子证据。
Clin Infect Dis. 2017 Oct 1;65(7):1222-1225. doi: 10.1093/cid/cix477.

使用他非诺喹治疗一名患有复发性巴贝斯虫病的患者，该患者具有对阿奇霉素和阿托伐醌耐药的临床及分子证据。

Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone.

作者信息

Marcos Luis A, Leung Annie, Kirkman Laura, Wormser Gary P

机构信息

Department of Medicine (Division of Infectious Diseases) and Department of Microbiology and Immunology, Stony Brook University, USA.

Department of Medicine (Division of Infectious Diseases) and Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA.

出版信息

IDCases. 2022 Feb 25;27:e01460. doi: 10.1016/j.idcr.2022.e01460. eCollection 2022.

DOI:10.1016/j.idcr.2022.e01460
PMID:35242564
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8885462/
Abstract

Tafenoquine is a highly effective treatment for infections in animal models. An immunocompromised patient infected by a strain of that was at least partially resistant to both azithromycin and atovaquone was treated with tafenoquine. Systematic clinical studies using tafenoquine for treating other patients with babesiosis should be considered.

摘要

他非诺喹是动物模型感染的高效治疗药物。一名免疫功能低下的患者感染了一种对阿奇霉素和阿托伐醌至少部分耐药的巴贝斯虫菌株，接受了他非诺喹治疗。应考虑开展使用他非诺喹治疗其他巴贝斯虫病患者的系统临床研究。